FDA approves J & amp;J's non-chemotherapy combination regimen for rare blood cancer
Approval expands the label for Imbruvica in WM to include combination use with rituximab (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 28, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 27, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenstr öm’s Macroglobulinemia
HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 27, 2018 Category: Drugs & Pharmacology Source Type: news

Rituximab in Takayasu Arteritis: An Unmet Hope Rituximab in Takayasu Arteritis: An Unmet Hope
Is there sufficient evidence to support the use of rituximab therapy for Takayasu arteritis? This editorial explores the issue.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL
MOR208, an Fc-engineered, humanized, CD19 antibody, shows promise in rituximab-refractory B-cell NHL and follicular lymphoma.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news